A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)
Latest Information Update: 12 Aug 2025
At a glance
- Drugs ALG-000184 (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms B-SUPREME
- Sponsors Aligos Therapeutics
Most Recent Events
- 29 Jul 2025 Status changed from not yet recruiting to recruiting.
- 09 May 2025 Status changed from planning to not yet recruiting.
- 06 May 2025 According to Aligos Therapeutics media release, the company has raised over $100M to begin this trial. The interim data for this study is expected in 2026 and topline data anticipated in 2027.